LWAC
ABBV icon

Laurel Wealth Advisors (California)’s AbbVie ABBV Stock Holding History

Laurel Wealth Advisors (California)’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$3.51M Buy
21,711
+164
+0.8% +$25.1K 0.35% 67
2022
Q3 		$2.89M Buy
21,547
+284
+1% +$40.8K 0.31% 79
2022
Q2 		$3.26M Buy
21,263
+370
+2% +$56.5K 0.33% 76
2022
Q1 		$3.39M Sell
20,893
-940
-4% -$137K 0.28% 85
2021
Q4 		$2.96M Buy
21,833
+4,692
+27% +$554K 0.23% 104
2021
Q3 		$1.85M Sell
17,141
-289
-2% -$33K 0.34% 59
2021
Q2 		$1.96M Sell
17,430
-660
-4% -$74.3K 0.25% 97
2021
Q1 		$1.96M Sell
18,090
-169
-0.9% -$18.1K 0.3% 83
2020
Q4 		$1.96M Buy
18,259
+97
+0.5% +$9.32K 0.29% 85
2020
Q3 		$1.59M Sell
18,162
-22
-0.1% -$2.07K 0.26% 90
2020
Q2 		$1.78M Buy
18,184
+1,220
+7% +$107K 0.33% 76
2020
Q1 		$1.29M Sell
16,964
-2,117
-11% -$180K 0.3% 86
2019
Q4 		$1.69M Sell
19,081
-4,826
-20% -$401K 0.28% 97
2019
Q3 		$1.81M Buy
23,907
+4,190
+21% +$287K 0.31% 80
2019
Q2 		$1.43M Buy
19,717
+1,536
+8% +$121K 0.31% 82
2019
Q1 		$1.47M Buy
18,181
+2,096
+13% +$171K 0.36% 73
2018
Q4 		$1.48M Sell
16,085
-890
-5% -$78.3K 0.44% 63
2018
Q3 		$1.6M Buy
16,975
+1,535
+10% +$146K 0.39% 64
2018
Q2 		$1.43M Sell
15,440
-82
-0.5% -$8.01K 0.38% 74
2018
Q1 		$1.47M Sell
15,522
-1,564
-9% -$172K 0.46% 58
2017
Q4 		$1.65M Buy
17,086
+1,700
+11% +$160K 0.48% 57
2017
Q3 		$1.37M Sell
15,386
-136
-0.9% -$10.4K 0.46% 66
2017
Q2 		$1.13M Buy
15,522
+1,679
+12% +$113K 0.4% 76
2017
Q1 		$902K Sell
13,843
-88
-0.6% -$5.53K 0.35% 81
2016
Q4 		$872K Sell
13,931
-428
-3% -$26.1K 0.39% 73
2016
Q3 		$906K Sell
14,359
-573
-4% -$37.1K 0.43% 66
2016
Q2 		$924K Buy
14,932
+156
+1% +$9.51K 0.44% 64
2016
Q1 		$844K Buy
14,776
+62
+0.4% +$3.46K 0.42% 67
2015
Q4 		$872K Buy
+14,714
New +$847K 0.45% 64

Other funds holding ABBV

AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Laurel Wealth Advisors (California)'s ABBV Position: Q4 2022 in Review

Laurel Wealth Advisors (California) increased its AbbVie (ABBV) stake by 0.76% in Q4 2022, buying an estimated $25.1K and bringing the position to 21,711 shares worth $3.51M. The position accounts for 0.35% of the portfolio, ranked #67.

Laurel Wealth Advisors (California) first reported a position in ABBV in Q4 2015 and has held it in 29 quarters since. 3,167 funds tracked by Wall St. Rank hold ABBV as of Q4 2022.

  • Laurel Wealth Advisors (California) held 21,711 shares of AbbVie worth $3.51M as of Q4 2022.
  • Laurel Wealth Advisors (California) bought 164 AbbVie shares in Q4 2022, an estimated $25.1K.
  • AbbVie made up 0.35% of Laurel Wealth Advisors (California)'s portfolio in Q4 2022, its #67 holding.
  • Laurel Wealth Advisors (California) first reported a position in AbbVie in Q4 2015 and has held it in 29 quarters since.
  • 3,167 funds tracked by Wall St. Rank held AbbVie as of Q4 2022.

Based on Laurel Wealth Advisors (California)'s 13F filing for Q4 2022, filed 14 Feb 2023.